Related Experiment Video
Updated: Jul 10, 2026

11:12
Tissue Engineering of a Human 3D in vitro Tumor Test System
Published on: August 6, 2013
Assessing TP53 status in human tumours to evaluate clinical outcome
1Institut Curie, Université P. & M. Curie, Laboratoire de Génotoxicologie des Tumeurs, Paris, France. thierry.soussi@curie.fr
Nature Reviews. Cancer
|March 21, 2002
Abstract:
TP53 is probably the most extensively studied tumour-suppressor gene, and patients with TP53 mutations are known to have a poor outcome. However, inconsistencies in the analysis of TP53 status, and failure to realize that different mutations behave in different ways, prevent us from effectively applying our vast knowledge of this protein in clinical practice. What simple steps can be taken to ensure that patients benefit from our understanding of TP53?

